Significant Activity of the mTOR Inhibitor Sirolimus and HDAC Inhibitor Vorinostat in Heavily Pretreated Refractory Hodgkin Lymphoma Patients
F Janku, I Garrido-Laguna, V Velez-Bravo, G Falchook, V Subbiah, D Hong, Y Oki, J Westin, C Nunez, L Fayad, L Kwak, S Neelapu, E Shpall, J Wheler, W Lang, B Salhia, F Meric-Bernstam, R Kurzrock, M Fanale · Klinische Pädiatrie · 2014 · Heft 03
Bibliografische Angaben
Zusammenfassung
Background: Preclinical models have suggested that HDAC and mTOR inhibitors have synergistic antineoplastic activity in Hodgkin lymphoma and other cancers by reducing the activity of AKT, mTOR and HDAC. Methods: We designed a phase I study to determine the safety of the mTOR inhibitor sirolimus (1 mg – 5 mg PO daily q 28 days) and HDAC inhibitor vorinostat (100 mg – 400 mg PO daily q 28 days) in advanced cancers with an expansion cohort at the recommended phase 2 dose (RP2D) of sirolimus 4 mg and vorinostat 300 mg for patients with refractory classical Hodgkin lymphoma. The expansion cohort included optional pre…
